Internal Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Nordstrom, D.C., et al. - Fewer than 40% of newly diagnosed patients with rheumatoid arthritis (RA) reach remission with a combination of traditional DMARDs, and therefore new effective therapies are still needed. Proinflammatory cytokines, such as TNF-alpha and IL-1, are important pathogenetic mediators in RA and related conditions. Targeted therapies against these cytokines and downstream inflammatory mediators have greatly added to the therapeutic arsenal and brought new hope to patients in providing physicians with new effective treatment options


Previous Article Next Article

Today in Clinical Pharmacology...keeping you current

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review
Annals of Rheumatic Diseases, 06/09/09

Denosumab update
Current Opinion in Rheumatology, 06/11/09

Dapsone 5 Gel: A Review of its Efficacy and Safety in the Treatment of Acne Vulgaris
American Journal of Clinical Dermatology, 06/09/09

Today in Rheumatology...keeping you current

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review
Annals of Rheumatic Diseases, 06/09/09

Denosumab update
Current Opinion in Rheumatology, 06/11/09

Serum urate during acute gout
Journal of Rheumatology, 06/12/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address